Genmab shares surge after late-stage trial of ovarian cancer drug Rina-S

Bloomberg reports Genmab shares surged the most in more than six years after its late-stage trial exceeded analyst expectations. Genmab said Rina-S cut the risk of disease progression or death by 71% in a group with platinum-resistant ovarian cancer, Bloomberg reports. For patients with an advanced form of ovarian cancer, Genmab said Rina-S cut the risk of death by 57% versus chemotherapy, The Wall Street Journal reports.